Zacks Research Expects Weaker Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Investment analysts at Zacks Research dropped their Q1 2026 earnings estimates for shares of Zimmer Biomet in a report released on Monday, May 26th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $1.88 per share for the quarter, down from their previous forecast of $2.12. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's FY2026 earnings at $8.06 EPS and Q1 2027 earnings at $2.09 EPS.

Several other equities analysts have also commented on the stock. The Goldman Sachs Group decreased their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. JPMorgan Chase & Co. decreased their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Canaccord Genuity Group decreased their target price on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Finally, JMP Securities decreased their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Price Performance

ZBH stock traded down $1.22 during mid-day trading on Thursday, hitting $92.12. The stock had a trading volume of 3,505,131 shares, compared to its average volume of 1,805,016. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a 52 week low of $89.92 and a 52 week high of $116.71. The firm has a market capitalization of $18.23 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.95 and a beta of 0.78. The firm has a fifty day simple moving average of $99.99 and a 200 day simple moving average of $104.80.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same quarter in the previous year, the company earned $1.94 EPS. The business's revenue was up 1.1% on a year-over-year basis.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Roman Butler Fullerton & Co. acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $473,000. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $7,825,000. Van ECK Associates Corp lifted its position in shares of Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares during the period. MFG Wealth Management Inc. acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $1,506,000. Finally, Gries Financial LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $866,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.